AQST News and Press, Aquestive Therapeutics Inc. From 01/06/23

Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for Libervant ™ (diazepam) Buccal Film accelerated market access Expects preli...

FDA continues to indicate that the Company can conduct a comparability study rather than efficacy studies FDA provides clear guidance on approvability expectations for pharmacokinetic (PK) performance and patient administration attributes Company continues to anticipate a potentia...

Summary Assertio Holdings is a pharmaceutical company based on a niche model that is focused on digital, non-personal promotion. Last Q3 showed great revenue and cash flow growth. The company's growth strategy is based on market acquisitions. The share price valuation seems to b...

WARREN, N.J., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today the publication of a crossover food effe...

WARREN, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the management team will participat...

WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data fro...

Summary After a rough September, we’re approaching the season historically known for stronger performance. Although small-cap stocks can be more volatile than large-caps, cheap stocks often have high return potential. Offering attractive valuations, above-average growth, an...

Aquestive Therapeutics, Inc. (AQST) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer ...

The following slide deck was published by Aquestive Therapeutics, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Aquestive Therapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation

Aquestive Therapeutics press release ( NASDAQ: AQST ): Q3 GAAP EPS of -$0.23 beats by $0.07 . Revenue of $11.46M (-13.7% Y/Y) beats by $0.42M . For further details see: Aquestive Therapeutics GAAP EPS of -$0.23 beats by $0.07, revenue of $11.46M beats by ...